Yazar "Uncu, Dogan" seçeneğine göre listele
Listeleniyor 1 - 9 / 9
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Association of obesity with breast cancer clinical and pathological factors: Analysis of Turkish National Breast Cancer Registry.(Amer Soc Clinical Oncology, 2015) Coskun, Ugur; Altundag, Kadri; Aliustaoglu, Mehmet; Uncu, Dogan; Ozkan, Metin; Cicin, Irfan; Ciltas, Aydin[Abstract Not Available]Öğe Breast cancer subtypes and the risk of distant relapse after breast conserving surgery or mastectomy: An Anatolian Society of Medical Oncology study.(Amer Soc Clinical Oncology, 2015) Kaplan, Muhammet Ali; Urakci, Zuhat; Uncu, Dogan; Dane, Faysal; Ozkan, Metin; Akman, Tulay; Harputluoglu, Hakan[Abstract Not Available]Öğe Characteristics of Turkish colorectal cancer patients and bevacizumab preference.(Amer Soc Clinical Oncology, 2017) Cicin, Irfan; Gumus, Mahmut; Uncu, Dogan; Ozkan, Metin; Kilickap, Saadettin; Elkiran, Tamer E.; Isikdogan, Abdurrahman[Abstract Not Available]Öğe Clinical features and prognostic factors in small bowel tumors: A retrospective evaluation of eighty cases(2020) Koc, Neriman Sila; Uncu, Dogan; Karaahmetoglu, SelmaAim: Small bowel tumors are rare tumors originating from the gastrointestinal tract. In this study, we aimed to determine the clinical characteristics and prognostic factors effecting survival in patients with small bowel cancer. Material and Methods: Eighty patients with small bowel malignancy between February 2002 and December 2016 were evaluated retrospectively. Clinical characteristics, pathological features, laboratory results, progression-free and overall survival rates were determined. The effect of the evaluated parameters on survival was examined.Results: The incidence of small bowel tumors was 0.36% in patients admitted to our clinic. The median age of the patients was 55 and 68.8% of the patients were male. The most common histologic subtype was adenocancer (42.5%), and the most common localization site (37.5%) was duodenum. 27 of patients (33.8%) had metastasis at the time of diagnosis. The most common site of metastasis was liver. Overall survival rate was 59.1% in the third year and 52.9% in the fifth year. The median disease-free survival (DFS) rate was 78% in the third year and 68% in the fifth year. Conclusion: Information about these tumors is limited in the literature and was presented in retrospective case series. In our study, the most common localization site was found as duodenum and the most common histological type was adenocancer. Prognosis of patients undergoing curative surgical resection was found to be better.Öğe Effect of body mass index in gastric cancer patients: Analysis of Turkish national gastric cancer registry(Amer Soc Clinical Oncology, 2015) Ciltas, Aydin; Karaca, Mustafa; Uncu, Dogan; Ozkan, Metin; Aliustaoglu, Mehmet; Tekin, Salim Basol; Cicin, Irfan[Abstract Not Available]Öğe Results of Adjuvant FOLFOX Regimens in Stage III Colorectal Cancer Patients: Retrospective Analysis of 667 Patients(Karger, 2013) Uncu, Dogan; Aksoy, Sercan; Cetin, Bulent; Yetisyigit, Tarkan; Ozdemir, Nuriye; Berk, Veli; Dane, FaysalObjective: The aim of this study was to assess the use of 5-fluorouracil (5-FU), leucovorin and oxaliplatin (FOLFOX) regimens in clinical practice according to their efficacy and toxicity. Methods: Patients who received oxaliplatin-containing regimens after curative resection for colorectal carcinoma from 10 different oncology centers between May 2004 and December 2009 were included in the study. All patients were treated with FOLFOX regimens. Patients with rectal carcinoma were also treated with chemoradiotherapy with 5-FU after 2 cycles of a FOLFOX regimen. Results: The median age of the patients was 56 years (range 17-78). Of the total 667 patients, 326 were given FOLFOX-4, 232 were given modified FOLFOX-4 and 109 were given FOLFOX-6. The distribution according to disease stage was 33 patients with stage IIIA colorectal cancer, 382 patients with stage IIIB and 252 patients with stage IIIC. The most common adverse events were neutropenia (54%), nausea (36.9%), neuropathy (38.2%) and anemia (33.1%) for all grades. The median follow-up time was 23 months (range 1-79). Three-year disease-free survival and overall survival were 65 and 85.7%, respectively. Conclusion: The different oxaliplatin-containing 5-FU-based adjuvant chemotherapy regimens in patients with stage III colorectal cancer seemed to be at least equal in terms of efficacy regardless of the method of 5-FU administration or oxaliplatin dose. Copyright (C) 2012 S. Karger AG, BaselÖğe Turkish Breast Cancer Registry: A multicenter epidemiologic study(Lippincott Williams & Wilkins, 2014) Coskun, Ugur; Gumus, Mahmut; Uncu, Dogan; Ozkan, Metin; Cicin, Irfan; Altundag, Kadri; Elklran, Tamer[Abstract Not Available]Öğe Turkish National Breast Cancer Registry.(Amer Soc Clinical Oncology, 2015) Altundag, Kadri; Dumanli, Esra; Aliustaoglu, Mehmet; Uncu, Dogan; Ozkan, Metin; Cicin, Irfan; Coskun, Ugur[Abstract Not Available]Öğe Turkish National Colon Cancer Registry.(Amer Soc Clinical Oncology, 2015) Benekli, Mustafa; Dumanli, Esra; Kilickap, Saadettin; Uncu, Dogan; Aliustaoglu, Mehmet; Cicin, Irfan; Gumus, Mahmut[Abstract Not Available]
